Gyomor- és nyelőcsőrák: vizsgálatok itt: Németország
57 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Magdeburg
- Életkor
- 18 év and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 - 3. fázisTaking peopleA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
- Where
- Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Jena, Kiel, Mainz, Munich, Nuremberg, Ravensburg, Schweinfurt, Ulm, Wolfsburg
- Életkor
- 18 év and over
- People
- 570 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00 - 1/2. fázisTaking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
- Életkor
- 18 év and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - 3. fázisTaking peopleA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hanover, Kiel, Leipzig, Mainz, Munich, Nuremberg, Saarbruecken, Schweinfurt, Wolfsburg
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - 2/3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Berlin, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, Mainz, Mannheim, Ulm
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - 1. fázisTaking peopleA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Erlangen, Essen, München
- Életkor
- 18 év and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - 1. fázisTaking peopleA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Essen
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - 1/2. fázisTaking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Berlin, Deggendorf, Hamburg
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - 1/2. fázisTaking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Bonn, Ulm
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - 1/2. fázisTaking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Dresden, Düsseldorf, Erdgeschoss, Heidelberg
- Életkor
- 18 év and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Frankfurt
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Where
- Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg, Tübingen
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00 - 1. fázisNot yet taking people in NémetországA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Cologne, Essen
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - 3. fázisTaking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Augsburg, Bad Saarow, Berlin, Brunswick, Chemnitz, Duesseldorf, Essen, Frankfurt am Main, Goettingen, Hamburg, Leipzig, Ludwigshafen Am Rhein, Luebeck, Mainz, Mannheim, Regensburg, Tuebingen, Ulm
- Életkor
- 18 év and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - 3. fázisTaking peopleSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Augsburg, Berlin, Bonn, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heilbronn, Leipzig, Magdeburg, Mainz, Marburg, Minden, Munich, Stuttgart, Ulm
- Életkor
- 18 év and over
- People
- 2130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00 - 1/2. fázisTaking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Berlin, Essen, Mainz, München, Tübingen
- Életkor
- 18 év and over
- People
- 1438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - 1/2. fázisTaking peopleA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Where
- Berlin, Düsseldorf, Erdgeschoss, Frankfurt am Main
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00 - 1/2. fázisTaking peopleSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Where
- Düsseldorf, Erdgeschoss, Heidelberg
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00 - 3. fázisTaking peoplePhase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Where
- Essen, Frankfurt, Mainz, Marburg
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Akeso
See details and how to joinNCT07700979 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Berlin, Essen, Hanover, München, Regensburg
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - 1/2. fázisTaking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Cologne, Esslingen am Neckar, Moers, Nuremberg
- Életkor
- 18 év and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551 - No phaseTaking peopleORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Where
- Hamburg, Heilbronn, Munich
- Életkor
- 18 év and over
- People
- 2285 worldwide
- Run by
- Guardant Health, Inc.
See details and how to joinNCT05059444 - 2. fázisTaking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Cologne, Frankfurt am Main, Gauting, Grosshansdorf, Hamburg, Heidelberg, Leipzig, Mainz, Muenster, Offenbach Am Main, Regensburg, Rheine
- Életkor
- 18 év to 64 év
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - 1/2. fázisTaking peopleSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Where
- Düsseldorf, Erdgeschoss, Heidelberg
- Életkor
- 18 év and over
- People
- 210 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06445972 · EU 2023-509306-29-00